Full Text View
Tabular View
No Study Results Posted
Related Studies
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
This study is ongoing, but not recruiting participants.
First Received: May 2, 2000   Last Updated: February 6, 2009   History of Changes
Sponsors and Collaborators: Nordic Society for Gynaecologic Oncology
European Organization for Research and Treatment of Cancer
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00005583
  Purpose

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy with chemotherapy is more effective than radiation therapy alone in treating high-risk endometrial cancer.

PURPOSE: This randomized phase III trial is studying radiation therapy and chemotherapy to see how well they work compared to radiation therapy alone in treating patients with high-risk endometrial cancer.


Condition Intervention Phase
Endometrial Cancer
Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: epirubicin hydrochloride
Procedure: adjuvant therapy
Procedure: conventional surgery
Radiation: radiation therapy
Phase III

MedlinePlus related topics: Cancer Radiation Therapy
Drug Information available for: Cisplatin Doxorubicin Doxorubicin hydrochloride Epirubicin hydrochloride Epirubicin Myocet
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control
Official Title: A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Progression-free survival [ Designated as safety issue: No ]
  • Relapse-free survival [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: January 2000
Detailed Description:

OBJECTIVES:

  • Compare relapse-free survival of patients with high-risk endometrial carcinoma treated in the adjuvant setting with either radiotherapy alone or radiotherapy and chemotherapy given sequentially.
  • Compare overall survival of this patient population treated with these 2 adjuvant regimens.
  • Evaluate the addition of chemotherapy to standard adjuvant radiotherapy, in terms of toxicity, in these patients.
  • Study whether the pattern of relapse in these patients is influenced by the addition of chemotherapy to adjuvant radiotherapy.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to center and histologic type (serous papillary and clear cell vs all other types). Patients are randomized to 1 of 2 treatment arms.

All patients undergo hysterectomy with bilateral salpingooophorectomy and extirpation of macroscopic suspicious lymph nodes.

  • Arm I: Within 7 weeks after surgery, patients begin radiotherapy.
  • Arm II: Patients receive radiotherapy followed by or preceded by chemotherapy*. Patients receive cisplatin IV over 60 minutes and doxorubicin or epirubicin IV over 10-20 minutes on day 1. Treament repeats every 21 days for 4 courses.

NOTE: *If radiotherapy is preceded by chemotherapy, radiotherapy begins within 4 weeks after chemotherapy.

Patients are followed at 3 and 6 months and then every 6 months for 5 years.

PROJECTED ACCRUAL: A total of 400 patients (200 per treatment arm) will be accrued for this study within 5 years.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed endometrial cancer of 1 of the following types:

    • Clear cell carcinoma
    • Serous papillary carcinoma
    • Undifferentiated (anaplastic) carcinoma
    • Poorly differentiated (FIGO grade 3) adenocarcinoma with infiltration to more than half the myometrial thickness
  • No small cell carcinoma with neuroendocrine differentiation
  • Primary in FIGO surgical stage I or occult stage II
  • No spread of disease outside the uterine corpus except to pelvic lymph nodes

    • No spread of disease to para-aortic lymph nodes
  • Positive peritoneal washings allowed
  • No preoperative macroscopic tumor involvement of the cervix

    • Microscopic tumor involvement of the cervix on histopathological evaluation of the operative uterine specimen allowed

PATIENT CHARACTERISTICS:

Age:

  • Any age

Performance status:

  • WHO 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • Adequate bone marrow function
  • WBC at least 3,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic:

  • Adequate hepatic function

Renal:

  • Adequate renal function
  • Creatinine no greater than 1.4 mg/dL

Pulmonary:

  • Adequate pulmonary function

Other:

  • Not pregnant or nursing
  • Fit to receive combination chemotherapy
  • No other malignancy except basal cell or squamous cell skin cancer
  • No uncontrolled or potentially active site of infection (e.g., fistula or abscesses)
  • No other concurrent condition that would produce a substantial increase in risk for complications from radiotherapy
  • No other concurrent condition that would interfere with adequate follow-up

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • Not specified

Endocrine therapy:

  • Not specified

Radiotherapy:

  • No prior preoperative irradiation

Surgery:

  • No prior extensive abdominal surgery
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005583

Locations
Belgium
Cazk Groeninghe - Campus Maria's Voorzienigheid
Kortrijk, Belgium, B-8500
Institut Jules Bordet
Brussels, Belgium, 1000
U.Z. Gasthuisberg
Leuven, Belgium, B-3000
Universitair Ziekenhuis Antwerpen
Edegem, Belgium, B-2650
France
Centre Henri Becquerel
Rouen, France, 76038
Ireland
Coombe Women's Hospital
Dublin, Ireland, 8
St. James's Hospital
Dublin, Ireland, 8
Italy
Azienda Ospedaliera Di Parma
Parma, Italy, 43100
Fondazione I.R.C.C.S. Policlinico San Matteo
Pavia, Italy, 27100
Istituto Nazionale per lo Studio e la Cura dei Tumori
Naples, Italy, 80131
Ospedale di Circolo e Fondazione Macchi
Varese, Italy, 21100
Netherlands
Medisch Spectrum Twente
Enschede, Netherlands, 7500 KA
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands, 1091 HA
Universitair Medisch Centrum St. Radboud - Nijmegen
Nijmegen, Netherlands, NL-6500 HB
Norway
Norwegian Radium Hospital
Oslo, Norway, N-0310
Poland
Medical University of Gdansk
Gdansk, Poland, 80-211
Portugal
Hospitais da Universidade de Coimbra (HUC)
Coimbra, Portugal, 3049
South Africa
Groote Schuur Hospital
Cape Town, South Africa, 7925
Spain
Hospital Universitario Central de Asturias
Oviedo, Spain, 33006
Hospital Universitario San Carlos
Madrid, Spain, 28040
United Kingdom, England
Nottingham City Hospital NHS Trust
Nottingham, England, United Kingdom, NG5 1PB
United Kingdom, Northern Ireland
Centre for Cancer Research and Cell Biology at Belfast City Hospital
Belfast, Northern Ireland, United Kingdom, BT9 7AB
United Kingdom, Scotland
Western Infirmary
Glasgow, Scotland, United Kingdom, G11 6NT
Sponsors and Collaborators
Nordic Society for Gynaecologic Oncology
European Organization for Research and Treatment of Cancer
Investigators
Study Chair: Gunnar B. Kristensen, MD, PhD Norwegian Radium Hospital
Investigator: Carlos F. de Oliveira, MD, PhD Hospitais da Universidade de Coimbra (HUC)
  More Information

Additional Information:
Publications:
Hogberg T, Rosenberg P, Kristensen G, et al.: A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). [Abstract] J Clin Oncol 25 (Suppl 18): A-5503, 274s, 2007.

Study ID Numbers: CDR0000067646, NSGO-EC9501, EORTC-55991
Study First Received: May 2, 2000
Last Updated: February 6, 2009
ClinicalTrials.gov Identifier: NCT00005583     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I endometrial carcinoma
stage II endometrial carcinoma
endometrial adenocarcinoma
endometrial papillary carcinoma
endometrial clear cell carcinoma

Study placed in the following topic categories:
Adjuvants, Immunologic
Genital Neoplasms, Female
Uterine Diseases
Urogenital Neoplasms
Endometrial Cancer
Epirubicin
Doxorubicin
Carcinoma
Genital Diseases, Female
Anti-Bacterial Agents
Endometrial Neoplasms
Adenocarcinoma, Clear Cell
Cisplatin
Carcinoma, Papillary
Uterine Neoplasms
Adenocarcinoma

Additional relevant MeSH terms:
Antineoplastic Agents
Genital Neoplasms, Female
Uterine Diseases
Urogenital Neoplasms
Antibiotics, Antineoplastic
Epirubicin
Pharmacologic Actions
Doxorubicin
Genital Diseases, Female
Endometrial Neoplasms
Neoplasms
Neoplasms by Site
Therapeutic Uses
Uterine Neoplasms

ClinicalTrials.gov processed this record on May 07, 2009